You can buy Avatodx at the lowest price at Nextgen.ooo online pharmacy. Avatrombopag is an orally available small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet count but not platelet activation. Patients with thrombocytopenia and chronic liver disease (leading to thrombocytopenia) often require platelet transfusions before surgery to reduce the risk of bleeding. Thrombocytopenia (or low platelet count) is a common complication in patients with chronic liver disease, either as a direct result of liver disease or as a consequence of interferon-based antiviral therapy.
 
Avatrombopag was approved by the FDA on May 21, 2018, for the treatment of thrombocytopenia (low platelet count) in adults with chronic liver disease. It is administered orally as avatrombopag maleate, its salt form.
 
Avatrombopag is a thrombopoietin receptor (TPOR; MPL) agonist that may have megakaryopoiesis-stimulating activity. Following administration, avatrombopag binds to and stimulates the platelet thrombopoietin receptor (TPOR), which may result in the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This process increases platelet production and may serve to prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is classified as a cytokine receptor and a member of the hematopoietin receptor superfamily.